These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34328095)

  • 21. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia].
    Wang JS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):229-33. PubMed ID: 23643015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
    Kashihara N; Kidokoro K; Kanda E
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
    Song J; Li X; Ni J
    Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
    Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
    Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 34. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
    León Jiménez D; Cherney DZI; Bjornstad P; Castilla-Guerra L; Miramontes González JP
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1406-F1415. PubMed ID: 30066584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
    Schernthaner G; Mogensen CE; Schernthaner GH
    Diab Vasc Dis Res; 2014 Sep; 11(5):306-23. PubMed ID: 25116004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
    Morillas C; D'Marco L; Puchades MJ; Solá-Izquierdo E; Gorriz-Zambrano C; Bermúdez V; Gorriz JL
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34070103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors.
    Guo W; Li H; Li Y; Kong W
    Biomed Pharmacother; 2023 Sep; 165():115025. PubMed ID: 37385209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New strategies to tackle diabetic kidney disease.
    Batu Demir D; Cooper ME
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
    Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
    Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.